These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1148 related articles for article (PubMed ID: 10223338)
1. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Kang CY; Luo L; Wainberg MA; Li Y Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338 [TBL] [Abstract][Full Text] [Related]
2. Induction of V3-specific cytotoxic T lymphocyte responses by HIV gag particles carrying multiple immunodominant V3 epitopes of gp120. Luo L; Li Y; Chang JS; Cho SY; Kim TY; Choi MJ; Cheong HS; Kim HJ; Ahn HJ; Min MK; Chun BH; Jung SM; Woo SG; Park SY; Kang CY Virology; 1998 Jan; 240(2):316-25. PubMed ID: 9454705 [TBL] [Abstract][Full Text] [Related]
3. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034 [TBL] [Abstract][Full Text] [Related]
4. Mapping of functional domains for HIV-2 gag assembly into virus-like particles. Luo L; Li Y; Dales S; Kang CY Virology; 1994 Dec; 205(2):496-502. PubMed ID: 7975251 [TBL] [Abstract][Full Text] [Related]
5. Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. Wagner R; Deml L; Schirmbeck R; Niedrig M; Reimann J; Wolf H Virology; 1996 Jun; 220(1):128-40. PubMed ID: 8659105 [TBL] [Abstract][Full Text] [Related]
6. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens. Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397 [TBL] [Abstract][Full Text] [Related]
7. Chimeric HIV-1 virus-like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit Gag- and SU-specific murine cytotoxic T-lymphocyte activities. Tobin GJ; Li GH; Fong SE; Nagashima K; Gonda MA Virology; 1997 Sep; 236(2):307-15. PubMed ID: 9325238 [TBL] [Abstract][Full Text] [Related]
8. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection. Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667 [TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model. Notka F; Stahl-Hennig C; Dittmer U; Wolf H; Wagner R Biol Chem; 1999 Mar; 380(3):341-52. PubMed ID: 10223337 [TBL] [Abstract][Full Text] [Related]
10. Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies. Luo L; Li Y; Cannon PM; Kim S; Kang CY Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10527-31. PubMed ID: 1438241 [TBL] [Abstract][Full Text] [Related]
11. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. McBurney SP; Young KR; Ross TM Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011 [TBL] [Abstract][Full Text] [Related]
12. Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles. Halsey RJ; Tanzer FL; Meyers A; Pillay S; Lynch A; Shephard E; Williamson AL; Rybicki EP Virus Res; 2008 May; 133(2):259-68. PubMed ID: 18329748 [TBL] [Abstract][Full Text] [Related]
13. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1. Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988 [TBL] [Abstract][Full Text] [Related]
14. Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development. Wagner R; Deml L; Schirmbeck R; Reimann J; Wolf H Behring Inst Mitt; 1994 Dec; (95):23-34. PubMed ID: 7755506 [TBL] [Abstract][Full Text] [Related]
15. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Deml L; Kratochwil G; Osterrieder N; Knüchel R; Wolf H; Wagner R Virology; 1997 Aug; 235(1):10-25. PubMed ID: 9300033 [TBL] [Abstract][Full Text] [Related]
16. Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Wagner R; Deml L; Fliessbach H; Wanner G; Wolf H Virology; 1994 Apr; 200(1):162-75. PubMed ID: 7510434 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses. Hewer R; Meyer D Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588 [TBL] [Abstract][Full Text] [Related]
18. Modifications of HIV-1 retrovirus-like particles to enhance safety and immunogenicity. Persson RH; Cao SX; Cates G; Yao FL; Klein MH; Rovinski B Biologicals; 1998 Dec; 26(4):255-65. PubMed ID: 10403029 [TBL] [Abstract][Full Text] [Related]
19. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma. Gómez CE; Abaitua F; Rodríguez D; Esteban M Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077 [TBL] [Abstract][Full Text] [Related]
20. Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses. Wagner R; Böltz T; Deml L; Modrow S; Wolf H J Gen Virol; 1993 Jul; 74 ( Pt 7)():1261-9. PubMed ID: 7687647 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]